atorvastatin has been researched along with Spondylitis, Ankylosing in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hisdal, J; Holme, I; Ikdahl, E; Kvien, TK; Pedersen, TR; Rollefstad, S; Semb, AG | 1 |
| Baeten, DL; Bernelot Moens, SJ; Nederveen, AJ; Nurmohamed, MT; Strang, AC; Stroes, ES; van der Valk, FM; Verberne, HJ; Verweij, SL | 1 |
2 other study(ies) available for atorvastatin and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.
Topics: Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Comorbidity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; Spondylitis, Ankylosing | 2015 |
Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy.
Topics: Adult; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Case-Control Studies; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Risk Factors; Spondylitis, Ankylosing; Treatment Outcome | 2016 |